An anticancer drug screen performed by the National Cancer Institute in a panel of 60 cancer cell lines including seven colorectal cancer cell lines demonstrated that the growth inhibition following the cisplatin treatment correlated with the presence of wildtype p53, while the lack of functional p53 was associated with resistance to cisplatin [100]. Here, TP53 is linked to cancer.